RUSSELL CRAWFORD: Open Payments
NPI 1225427388 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$320 in 17 payments from 9 companies in 2025. Trend: 2023 $633 · 2024 $1,181 · 2025 $320
Food & beverage: $320
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $93 |
| PFIZER INC. | 3 | $59 |
| Boston Scientific Corporation | 2 | $40 |
| Kestra Medical Technology Services, Inc. | 1 | $33 |
| Amgen Inc. | 2 | $30 |
| Novo Nordisk Inc | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
Products named: LEQVIO, VYNDAQEL, CDS - MCT/CEM Monitoring, Assure WCD, ELIQUIS, Ozempic, FARXIGA, REPATHA.
Industry payments across KY — which companies pay providers there.
